---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-24-001473"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2024-10-02T23:59:59+00:00"
generated_at: "2026-05-30T22:13:55.139528+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lexaria Bioscience appoints Michael Shankman as CFO, effective Oct 1, 2024

## Summary
- Michael Shankman, CPA, replaces resigned CFO Nelson Cabatuan; CEO Richard Christopher had been interim principal financial officer.
- Shankman previously served as outsourced CFO via NowCFO from June 2023 to February 2024.
- Compensation: base salary with inflation-adjusted annual increases; performance bonuses up to 35-50% of base salary.
- Granted incentive stock option for 50,000 shares at $3.17 exercise price, vesting in three tranches through August 31, 2026.
- Severance: if terminated without cause after 6 months, two months' base salary plus one additional month per year of service.

## SEC filing metadata
- accession: 0001640334-24-001473
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2024-10-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033424001473/0001640334-24-001473-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033424001473/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-24-001473
- JSON: https://secwatch.observer/filing/0001640334-24-001473.json
- Plain text: https://secwatch.observer/filing/0001640334-24-001473.txt

## Key facts
- Executive change
  Nelson Cabatuan resigned as Chief Financial Officer at Lexaria Bioscience Corp..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: replacing Lexaria’s former CFO, Nelson Cabatuan who resigned effective July 15, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348362/000164033424001473/0001640334-24-001473-index.htm
- Executive change
  Richard Christopher changed role as principal financial officer (interim) at Lexaria Bioscience Corp..
  - Action: relinquished responsibilities
  - Role: principal financial officer (interim)
  source text: Richard Christopher, the Company’s Chief Executive Officer who assumed the responsibilities as the Company’s principal financial officer on an interim basis, relinquished those responsibilities to Mr. Shankman.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348362/000164033424001473/0001640334-24-001473-index.htm
- Executive change
  Michael Shankman was appointed as Chief Financial Officer at Lexaria Bioscience Corp..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: Effective October 1, 2024, Michael Shankman, age 64, has been appointed to the position of Chief Financial Officer of Lexaria Bioscience Corp.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348362/000164033424001473/0001640334-24-001473-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.